Abstracts tagged "registry"

Abstract Number: 1632 • ACR Convergence 2023
Incident Malignancies in Patients with Rheumatoid Arthritis in Daily Rheumatological Care
Martin Schaefer¹, Yvette Meissner¹, Bernhard Manger², Sylvia Berger³, Karin Rockwitz⁴, Anne Regierer⁵ and Anja Strangfeld¹, ¹German Rheumatism Research Center, Berlin, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ³Rheumatologist, Naunhof, Germany, ⁴Rheumatologist, Goslar, Germany, ⁵Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany
Background/Purpose: In 2021, the European and US-American regulatory agencies EMA and FDA issued warnings about malignancy risk associated with the Janus kinase inhibitor (JAKi) tofacitinib…
Abstract Number: 0987 • ACR Convergence 2023
Risk Factors and Predictors of Disease Activity in Rheumatoid Arthritis and Psoriatic Arthritis: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
Vijaya Rivera Terán¹, David Vega Morales², Miguel Angel Saavedra Salinas³, Iris Colunga⁴, Sandra Carrillo Vazquez⁵, Dafhne Miranda Hernández⁶, Sergio Durán Barragán⁷, Erick Adrián Zamora Tehozol⁸, Daniel Xavier Xibillé Friedman⁹, Angel Alejandro Castillo Ortiz¹⁰, Sandra Sicsik Ayala¹¹, Fedra Irazoque Palazuelos⁵, Julio César Casasola Vargas¹², Angelica Peña¹³, Omar Eloy Muñoz Monroy¹⁴, Azucena Ramos Sánchez², Luis Valdés Corona¹⁵, Javier Merayo-Chalico¹⁶, Estefania Torres Valdez¹³, Aleni Paz Viscarra¹⁵, Samara Mendieta Zerón¹⁷ and Deshiré Alpízar Rodríguez¹, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Instituto Mexicano del Seguro Social, Monterrey, Mexico, ³IMSS, Mexico City, Mexico, ⁴Hospital Universitario UANL, Monterrey, Mexico, ⁵Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, ⁶Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁷Consulta Privada, Guadalajara, Mexico, ⁸Centro Médico Pensiones, Mérida, Mexico, ⁹Práctica Privada, Cuernavaca, Mexico, ¹⁰Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mérida, Mexico, ¹¹Instituto Mexicano del Seguro Social, Torreón, Mexico, ¹²Instituto de Seguridad Social del Estado de México y Municipios, Mexico City, Mexico, ¹³Instituto Mexicano del Seguro Social, Querétaro, Mexico, ¹⁴Hospital Central Militar, Mexico City, Mexico, ¹⁵Práctica Privada, Mexico City, Mexico, ¹⁶Reumátika, Centro de Vanguardia en Reumatología de la Ciudad de México, Mexico City, Mexico, ¹⁷Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico
Background/Purpose: Genetic, demographic, clinical, and immunological factors have been related with the response to treatment in inflammatory rheumatic diseases, such as rheumatoid arthritis (RA) and…
Abstract Number: 1692 • ACR Convergence 2023
Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)
Romain Aymon¹, Denis Mongin², Burkhard Leeb³, Monika Mustak-Blagusz⁴, Jakub Závada⁵, Karel Pavelka⁶, Dan Nordstrom⁷, Nina Trokovic⁸, Florenzo Iannone⁹, Catalin Codreanu¹⁰, Ziga Rotar¹¹, Tore Kvien¹², Sella Provan¹³, Manuel Enrique Pombo Suarez¹⁴, Fernando Alonso¹⁵, Fatos Onen¹⁶, Nevsun Inanc¹⁷, Louis Coupal¹⁸, Denis Choquette¹⁹, Galina Lukina²⁰, Ori Elkayam²¹, Victoria Furer²¹, Ana Maria Rodrigues²², Delphine COURVOISIER²³, Axel Finckh²⁴, Michael Nissen² and Kim Lauper²⁵, ¹Geneva University Hospitals, Collonges-sous-Salève, France, ²Geneva University Hospitals, Geneva, Switzerland, ³BioReg, Stockerau, Austria, ⁴BioReg, Vienna, Austria, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁷Helsinki University Hospital, Helsinki, Finland, ⁸University of Helsinki, Helsinki, Finland, ⁹Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ¹⁰Center for Rheumatic Diseases, Bucharest, Romania, ¹¹University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹²Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹³Diakonhjemmet Hospital, Oslo, Norway, ¹⁴Hospital Clínico Universitario, Santiago de Compostela, Spain, ¹⁵Spanish Society of Rheumatology, Madrid, Spain, ¹⁶Division of Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ¹⁷Division of Rheumatology, Medical School, Marmara University, Istanbul, Turkey, ¹⁸Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁹Centre hospitalier de l'Université de Montréal (CHUM), Université de Montréal, Montréal, QC, Canada, ²⁰Federal state budgetary scientific institution "V.A. Nasonova Research Institute of Rheumatology", Moscow, Russia, ²¹Tel Aviv Medical Center, Tel Aviv, Israel, ²²Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ²³Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²⁴HUG, Geneva, Switzerland, ²⁵Geneva University Hospitals, Genève, Switzerland
Background/Purpose: JAK-inhibitors (JAKi) are increasingly being prescribed to treat various inflammatory conditions, including psoriatic arthritis (PsA). While the understanding of JAKi efficacy and safety in…
Abstract Number: 0988 • ACR Convergence 2023
Elderly Patients’ Discontinuation of Biologic DMARDs in Patients with Rheumatic Diseases: Data from the Mexican Adverse Events Registry (BIOBADAMEX)
Vijaya Rivera Terán¹, David Vega Morales², Miguel Angel Saavedra Salinas³, Daniel Xavier Xibillé Friedman⁴, Iris Colunga⁵, Sandra Carrillo Vazquez⁶, Dafhne Miranda Hernández⁷, Sergio Durán Barragán⁸, Erick Adrián Zamora Tehozol⁹, Angel Alejandro Castillo Ortiz¹⁰, Sandra Sicsik Ayala¹¹, Fedra Irazoque Palazuelos⁶, Julio César Casasola Vargas¹², Angelica Peña¹³, Omar Eloy Muñoz Monroy¹⁴, Azucena Ramos Sánchez², Luis Valdés Corona¹⁵, Javier Merayo-Chalico¹⁶, Estefania Torres Valdez¹³, Aleni Paz Viscarra¹⁵ and Deshiré Alpízar Rodríguez¹, ¹Colegio Mexicano de Reumatología, Mexico City, Mexico, ²Instituto Mexicano del Seguro Social, Monterrey, Mexico, ³IMSS, Mexico City, Mexico, ⁴Práctica Privada, Cuernavaca, Mexico, ⁵Hospital Universitario UANL, Monterrey, Mexico, ⁶Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mexico City, Mexico, ⁷Instituto Mexicano del Seguro Social, Mexico City, Mexico, ⁸Consulta Privada, Guadalajara, Mexico, ⁹Centro Médico Pensiones, Mérida, Mexico, ¹⁰Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Mérida, Mexico, ¹¹Instituto Mexicano del Seguro Social, Torreón, Mexico, ¹²Instituto de Seguridad Social del Estado de México y Municipios, Mexico City, Mexico, ¹³Instituto Mexicano del Seguro Social, Querétaro, Mexico, ¹⁴Hospital Central Militar, Mexico City, Mexico, ¹⁵Práctica Privada, Mexico City, Mexico, ¹⁶Reumátika, Centro de Vanguardia en Reumatología de la Ciudad de México, Mexico City, Mexico
Background/Purpose: The approach to elderly patients (≥60 years) with rheumatic diseases offers certain difficulties and uncertainties. Older adults are a particularly vulnerable group who often…
Abstract Number: 1850 • ACR Convergence 2023
Long-term Glucocorticoid Use in a Cohort of Elderly Early Rheumatoid Arthritis Patients: A Joint Analysis of Medicare and the Rheumatology Informatics System for Effectiveness (RISE) Data
Andriko Palmowski¹, Eric Roberts², Jing Li², Emma Kersey², Rachael Stovall², Frank Buttgereit³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²University of California San Francisco, San Francisco, CA, ³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ⁴University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁵UCSF / SFVA, San Francisco, CA
Background/Purpose: According to recent ACR and EULAR rheumatoid arthritis (RA) guidelines, glucocorticoids (GCs) should only be used for brief periods or not at all. Our…
Abstract Number: 0139 • ACR Convergence 2023
Systemic Vasculitides in Portugal and Brazil: Preliminary Results from the Reuma.pt/vasculitis Registry
Mariana de Aguiar¹, Alexandre wagner Silva de Souza², Joana Martinho³, Adriana Carones⁴, Ana Beatriz Bacchiega de Freitas⁵, Ana Catarina Duarte⁶, Ana Filipa Águeda⁷, Camila Souto Oliveira Elias⁸, Catarina Cortesão⁹, Catarina Soares¹⁰, Carla Macieira¹¹, Carlos Eduardo Garcez Teixeira¹², Daniela Peixoto¹³, Duarte Vinha³, Estela Nogueira³, Fabricia Simil¹⁴, Francisca Guimarães¹³, Frederico Rajão Martins¹⁵, Gilda Ferreira¹⁶, Helena Assunção⁴, Heloisa Rulff⁸, Jorge Pestana Lopes⁶, José Costa³, Julia Medeiros¹⁷, Lilian Santos Porto¹⁸, Luiz Felipe Adsuara¹⁷, Manuella Ochtrop⁸, Maria João Gonçalves¹⁹, Mariana Diz Lopes²⁰, Matheus Vieira²¹, Nikita Khmelinskii¹¹, Rita Torres²², Sarah Neaime¹, Vitor Teixeira²³, Zoraida Sachetto¹² and Cristina Ponte²⁴, ¹Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Division of Rheumatology, Medical School, Universidade Federal de São Paulo, São Paulo, Brazil, ³Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ⁴Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁵Faculdade de Ciências da Saúde de Barretos, Barretos, Brazil, ⁶Hospital Garcia de Orta, Almada, Portugal, ⁷Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal, ⁸Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Instituto Português de Reumatologia, Lisboa, Portugal, ¹⁰Centro Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal, ¹¹Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ¹²Universidade Estadual de Campinas, Campinas, Brazil, ¹³Centro Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ¹⁴Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ¹⁵Department of Rheumatology, University Hospital Centre of Algarve, Faro, Portugal, ¹⁶Federal University of Minas Gerais, Belo Horizonte, Brazil, ¹⁷Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ¹⁸Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Brazil, ¹⁹Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, ²⁰Centro Hospitalar Universitário de São João, Porto, Portugal, ²¹Universidade Federal de São Paulo; Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ²²Hospital Egas Moniz, Lisboa, Portugal, ²³Hospital de Faro, CHUA, Lisbon, Portugal, ²⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
Background/Purpose: The epidemiology of vasculitis varies widely across different geographic areas of the world which may be due to different ethnic and environmental factors. Brazil…
Abstract Number: 1024 • ACR Convergence 2023
Relationship Between Race and Ethnicity, Time to Diagnosis, and Disease Activity for Children with Juvenile Idiopathic Arthritis in the CARRA Registry
Sarah McGuire¹, Tania Atanassova², Joanna Madej², Manuel Jimenez², Daniel Horton¹ and for the CARRA TMJ Arthritis Workgroup³, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers, Robert Wood Johnson Medical School, New Brunswick, NJ, ³Childhood Arthritis and Rheumatology Research Alliance, Washington, DC
Background/Purpose: Compared to non-Hispanic White children, Black children diagnosed with juvenile idiopathic arthritis (JIA) have more severe disease at diagnosis and worse outcomes, such as…
Abstract Number: 1903 • ACR Convergence 2023
Assessing Disparities Through Missing Race and Ethnicity Data: Results from a Juvenile Arthritis Registry
Katelyn Banschbach¹, Jade Singleton², Esi Morgan² and Xing Wang³, ¹University of Washington, Seattle, WA, ²Seattle Children's Hospital, Seattle, WA, ³Biostatistics Epidemiology and Analytics in Research (BEAR), Seattle Children’s Research Institute, Seattle, WA
Background/Purpose: Research databases are missing 25-50% of race and ethnicity, typically related to Black and Hispanic data.1,2The absence of this data can lead to inaccurate…
Abstract Number: 0355 • ACR Convergence 2023
Long Term Safety of Drugs in Systemic Juvenile Idiopathic Arthritis
Ana Isabel Rebollo Gimenez¹, Luca Carlini², Paivi Miettunen³, Ekaterina Alexeeva⁴, Charlotte Myrup⁵, Rebecca Nicolai⁶, Maria Trachana⁷, Valda Stenevicha⁸, Constantin Ailioaie⁹, Elena Tsitsami¹⁰, Alexis-Virgil Cochino¹¹, Chiara Pallotti¹², Silvia Scala¹², Angela Pistorio¹³, Sebastiaan Vastert¹⁴, Joost Swart¹⁵ and Nicolino Ruperto¹⁶, ¹IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, ³University of Calgary and Alberta Children’s Hospital, Calgary, AB, Canada, ⁴Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation, Moscow, Russia, ⁵Pediatric rheumatology unit 4272, Rigshospitalet, Copenhagen, Denmark, ⁶Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ⁷First Department of pediatrics, Pediatric Immunology and Rheumatology Referral Center, Hippokration General Hospital, Thessaloniki University School of Medicine, Thessaloniki, Greece, ⁸Department of Paediatrics, Riga Stradins University, Children University Hospital, Riga, Latvia, ⁹Pediatric Rheumatology , Alexandru Ioan Cuza University of Iasi, Iasi, Romania, ¹⁰Pediatric Rheumatology Unit, 1st Department of Pediatrics, Children's Hospital "Aghia Sophia", University of Athens, Athens, Greece, ¹¹First Department of Pediatrics, University of Athens Medical School, Aghia Sophia Childrens Hospital, Athens, Greece, ¹²Pediatric and Rheumatology Clinic, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹³Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genoa, Italy, ¹⁴University Medical Center Utrecht, Utrecht, Netherlands, ¹⁵Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Netherlands, ¹⁶IRCCS Istituto Giannina Gaslini, UOSID Centro Trial, Genova, Italy
Background/Purpose: Evidence on treatment safety in systemic juvenile idiopathic arthritis (sJIA) is limited. Our objective was to evaluate the safety profile of drugs in the…
Abstract Number: 1085 • ACR Convergence 2023
Utilizing a Maintenance of Certification (MOC) Part 4 Quality Improvement Project to Improve Data Completeness in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry
Hemalatha Srinivasalu¹, anne dennos², alan Russell³, Mary Beth Son⁴ and Mara Becker², ¹Children's National Hospital, Washington, DC, ²Duke University, Durham, NC, ³Duke Clinical Research Institute, Duke, NC, ⁴Division of Immunology, Boston Children's Hospital, Boston, MA
Background/Purpose: Minimizing missing data in research registries is a universal challenge. Enrolling patients into a research registry with poor data quality is wasteful and potentially…
Abstract Number: 1964 • ACR Convergence 2023
Penn State Registry of Inflammatory Myopathies (PRIMO) Provides Insights into Disease Features and Co-Morbidity Screening Utilization
Jacob Colello¹, Kirsten Riggle¹, Galen Foulke², Peri Newman¹, Jamie Carter¹ and Nancy Olsen¹, ¹TE-Penn State MS Hershey Medical Center, Hershey, PA, ²Penn State MS Hershey Medical Center, Hershey, PA
Background/Purpose: Dermatomyositis (DM) is a relatively rare condition with significant morbidity and mortality across the lifespan.Recent advances in diagnostics and therapeutics have significant potential to…
Abstract Number: 0377 • ACR Convergence 2023
Disease Activity and New Medication Start at Two Consecutive Registry Visits for Patients with Juvenile Idiopathic Arthritis
Melissa Mannion¹, Monica Aswani², Kristine Hearld², Emily Smitherman², Livie Huie³ and Jeffrey R Curtis⁴, ¹University of Alabama at Brimingham, Birmingham, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Gardendale, AL, ⁴Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL
Background/Purpose: The goal of treatment for patients with juvenile idiopathic arthritis (JIA) is inactive or minimal disease activity and escalating medication for active disease is…
Abstract Number: 1095 • ACR Convergence 2023
Engagement with the RISE Registry Clinician Dashboard Is Associated with Higher Performance on Rheumatology Quality Measures
Emma Kersey¹, Jing Li¹, Julia Kay¹, Julia Adler-Milstein¹, Jinoos Yazdany² and Gabriela Schmajuk³, ¹University of California San Francisco, San Francisco, CA, ²University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ³UCSF / SFVA, San Francisco, CA
Background/Purpose: The American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) EHR-based registry facilitates quality measure calculation and reporting for rheumatology practices in national…
Abstract Number: 2114 • ACR Convergence 2023
The Relationship Between Disease Activity of Rheumatoid Arthritis and Kidney Function
Sho Fukui¹, Wolfgang Winkelmayer², Sara Tedeschi¹, Javier Marrugo¹, Hongshu Guan¹, Leslie Harrold³, Heather Litman³, Tomohiro Shinozaki⁴ and Daniel Solomon⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Baylor College of Medicine, Houston, TX, ³CorEvitas, LLC, Waltham, MA, ⁴Tokyo University of Science, Tokyo, Japan, ⁵Brigham and Women's Hospital, Newton, MA
Background/Purpose: Chronic kidney disease (CKD) is a common comorbidity of rheumatoid arthritis (RA) affecting 10-20% of patients. However, the influence of the longitudinal RA disease…
Abstract Number: 0432 • ACR Convergence 2023
Predictors of Use, Survival and Safety of Tofacitinib Monotherapy vs. in Combination with CsDMARDs in Daily Clinical Practice
Rodolfo Perez-Alamino¹, Carolina Isnardi², Enrique Soriano³, Luciano Lo Giudice⁴, johana zacariaz hereter⁴, Gustavo Casado⁵, Victor Caputo⁵, Andrea Schmichowski⁵, Cecilia Romeo⁵, Estela Rivero⁵, Florencia Savy⁶, Mercedes García⁷, Olga Romano¹, Hernan Maldonado Ficco⁸ and Gustavo Citera², ¹Hospital Avellaneda, Tucuman, Argentina, ²IREP, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Services, Hospital Italiano de Buenos Aires, and University Institute Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Hospital Militar Central, Buenos Aires, Argentina, ⁶HIGA San Martin, La Plata, Argentina, ⁷Hospital Interzonal General de Agudos José de San Martín, La Plata, Argentina, ⁸Hospital San Antonio de Padua, Río Cuarto, Argentina
Background/Purpose: Different guidelines recommend the use of tofacitinib either in monotherapy or combined with methotrexate (combination therapy) in patients with rheumatoid arthritis (RA) with an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].